Skip to main
ACOG

ACOG Stock Forecast & Price Target

ACOG Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Cognition Inc. is positioned for a positive financial trajectory due to its focus on the commercialization of ZUNVEYL, which addresses a critical need in the market for neurodegenerative diseases. Expectations of a significant advancement in sales as contracting is implemented, combined with a forecasted acceleration in 2026 that could broaden outreach to neurologists, support a favorable outlook for revenue growth. Additionally, a projected year-end 2025 cash balance of approximately $63 million suggests that the company has adequate financial resources to sustain operations towards achieving profitability.

Bears say

Alpha Cognition Inc. has reduced its net sales forecast for 2025 to $5.7 million from $11.7 million, reflecting anticipated delays in contracting and reimbursement processes for its lead product, ZUNVEYL. Potential risks include challenges in launching ZUNVEYL timely, slow market uptake due to competitive pressures, and the likelihood of clinical development setbacks, all of which could hinder future growth. Additionally, concerns about medium- to long-term equity dilution impact the perception of the company's financial stability and growth potential.

ACOG has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Cognition Inc (ACOG) Forecast

Analysts have given ACOG a Strong Buy based on their latest research and market trends.

According to 1 analysts, ACOG has a Strong Buy consensus rating as of Mar 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Cognition Inc (ACOG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.